Results 251 to 260 of about 3,332,191 (309)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source

Multi-sector perspectives on opportunities to increase WIC enrollment through community healthcare partnerships. [PDF]

open access: yesFront Health Serv
Allen SE   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy